Le Lézard
Classified in: Health
Subjects: NPT, PSF, AVO

ECRI Institute Opposes Proposed Ban of Ethylene Oxide (EtO) Sterilization Operations


PLYMOUTH MEETING, Pa., Nov. 7, 2019 /PRNewswire/ -- ECRI Institute, the nation's leading independent, non-profit patient safety organization, opposes a total ban of commercial ethylene oxide (EtO) sterilization because it could result in widespread shortages of sterile medical devices. More than fifty percent of all sterile medical devices purchased in the United States are sterilized with EtO.

ECRI Institute logo. (PRNewsFoto/ECRI Institute)

"Even a partial ban on ethylene oxide could cripple the delivery of healthcare in the United States as critical medical-surgical supplies would suddenly become unavailable," said Marcus Schabacker, MD, PhD, president and CEO, ECRI Institute.

Hospitals around the country began reporting medical device shortages after a large Illinois-based sterilization plant closed due to state environmental pressures. Legislators in Illinois are currently considering an outright ban on EtO sterilization. These actions follow a 2016 report by the Environmental Protection Agency (EPA) regarding possible health risks from EtO emissions.

"While environmental health concerns certainly need to be addressed, legislators and the public should be aware that an ethylene oxide ban could severely impact the safe delivery of healthcare," said Schabacker. "Without access to medical supplies, many surgeries and procedures would not be possible."

For more than 50 years, the medical device industry has relied on ethylene oxide to sterilize temperature- and moisture-sensitive disposable medical devices, such as syringes, IV bags, and wound dressings, and lifesaving devices, such as stents and catheters. These medical device materials and packaging were developed for EtO sterilization. ECRI Institute knows of no safe alternative commercial sterilization methods that could immediately replace EtO at this time.

This topic is under discussion at the Food and Drug Administration (FDA) public advisory committee meeting of the General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee, November 6-7, 2019.

To learn more, contact ECRI Institute at [email protected], (610) 825-6000, or visit www.ecri.org.

Social Sharing
.@ECRI_ Institute opposes proposed ban of #ethyleneoxide (#EtO) #sterilization operations, cites device shortages & risks to #patient care

About ECRI Institute

ECRI Institute is an independent, nonprofit organization improving the safety, quality, and cost effectiveness of care across all healthcare settings. The combination of evidence-based research, medical device testing, and knowledge of patient safety makes ECRI uniquely respected by healthcare leaders and agencies worldwide. For more than 50 years, ECRI Institute has had an unwavering dedication to transparency and strict conflict-of-interest policies. The organization has earned a reputation as the trusted voice of unbiased, research-based assurance for tens of thousands of members around the world using its solutions to minimize risk and improve patient care.

ECRI Institute has the only medical device testing labs in North America and the Asia Pacific where biomedical engineers conduct hands-on independent device testing for safety and human factors usability. ECRI Institute is designated an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality. ECRI Institute PSO is listed as a federally certified Patient Safety Organization by the U.S. Department of Health and Human Services.

Visit www.ecri.org and follow @ECRI_Institute to learn more.

SOURCE ECRI Institute


These press releases may also interest you

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...

at 03:03
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark. With the solution, they aim to elevate the educational...

at 03:00
Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).  ...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...



News published on and distributed by: